Polymorfizmus v promotorové oblasti genu pro MMP-2 u revmatoidní artritidy
[Polymorphism of gene promotor region for MMP-2 in rheumatoid arthritis]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article
PubMed
16755991
- MeSH
- Adult MeSH
- Genetic Predisposition to Disease MeSH
- Middle Aged MeSH
- Humans MeSH
- Matrix Metalloproteinase 2 genetics MeSH
- Polymorphism, Genetic * MeSH
- Promoter Regions, Genetic genetics MeSH
- Arthritis, Rheumatoid genetics MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Names of Substances
- Matrix Metalloproteinase 2 MeSH
INTRODUCTION: Matrix metalloproteinase (MMP) belonging to family of zinc-dependent endopeptidases participates in remodelling of extracellular matrix in many physiological and pathological processes including rheumatoid arthritis (RA). Rheumatoid arthritis is a chronic autoimmune inflammatory multi-systemic disease characterized, among others, by degradation of hyaline articular cartilage and escalated angiogenesis. As a matter of fact, these processes may by influenced by MMP. On the other hand, MMP can suppress inflammation by degrading biologically active molecules like cytokines, chemokines or growth factor receptors. Increased levels of MMP-2 (gelatinase A) are observed in serum and synovial fluid of patients with RA. Gene polymorphism for MMP-2 can affect susceptibility to development and/or severity of RA. METHOD: The aim of the study was to prove possible association of polymorphisms in gene promotor region for MMP-2 (-1575 G/A, -1306 C/T, -790 T/G, -735 C/T) with RA. We worked with 101 patients with RA who met reviewed diagnostic criteria of ACR (1987) for RA, and suffer from RA for at least 2 years. Control group consisted of 101 healthy volunteers of similar age and gender distribution. RESULTS: RA patients and control group did not differ in genotype distributions or frequencies of alleles of polymorphisms -1575A/G, -1306C/T and -735 C/T. Significant difference was observed between RA patients and control group in allelic frequencies of polymorphism -790 T/G MMP-2 (T allele -0.70 vs. 0.66, Pa = 0.013). Also, a tendency of GG genotype growth was noted in RA patients (Pg = 0.053). Significant difference in allelic frequencies was also observed between men with RA and men from control group (T allele -0.80 vs. 0.61, Pa = 0.025). Haplotype of GCGC polymorphisms -1575 G/A, -1306 C/T, 790 T/G, -735 C/T was more frequent in RA patients (Pcorr = 0.016; OR = 0.09; confidence interval 0.00-0.65), whereas GCTC haplotype was noted more frequently in control group (Pcorr = 0.017; OR = 1.8; confidence interval 1.17-2.70). CONCLUSION: The results indicate the association between polymorphisms in gene promotor region for MMP-2 and susceptibility to development of RA.